From the Department of Medicine, Divisions of G e n e ra l internal Medicine and 4Haematology, 2Central Haematological Laboratory, 3Clinical Vascular Laboratory, University Hospital Nijmegen, The Netherlands Summary was demonstrated that more than 50% of vein thrombi undergo complete resolution 3 to 6 months after diagnosis (3) (4) (5) . A number of studies evaluating deep venous thrombosis (DVT)
Regression of DVT depends on a balance between haemostatic and have demonstrated that plasma levels of thrombotic and fibrinolytic fibrinolytic factors, Measurement of D-Dimer (DD), a specific fibrin parameters change during treatment, but the relationship between degradation product, has proven to be useful for the diagnostic thrombus regression and evolution of these markers remains unknown, management of DVT (6) (7) (8) . A number of studies have demonstrated The objective of the present study was to correlate levels of D-Dimer that plasma levels of DD and other markers decrease during heparin (DD) with thrombus regression as assessed by duplex scanning.
therapy, but the relationship between thrombus regression and evoluFrom 44 patients treated for acute DVT, DD were determined at tion of the markers remains unknown (9) (10) (11) . diagnosis and at the end of initial heparin therapy of at least 5 days.
A plasma marker that has predictive value for the outcome of a DVT Thrombus regression was measured by repeated duplex scanning at is valuable for the long-term management of DVT, The objective of this diagnosis and after 1 and 3 months.
DD significantly decreased during heparin treatment as compared with values at presentation. DD levels were significantly higher in the group of patients without normalization of the DVT after 3 months (p = 0.003). A ninefold excess tendency was seen for DD levels Methods > 1200 ng/ml at the end of initial treatment to be associated with poor Patients resolution of the DVT [odds ratio 9.0, 0.95 confidence interval (Cl) 2.3-35.4]. When the patients with an established malignancy were excluded, the differences were even more significant (p = 0.0004 for DD levels after initial treatment and an odds ratio of 17.5, 0,95 Cl 3.3-92.5).
These results suggest that increased DD levels after the initial phase of treatment are related to poor resolution of DVT after 3 months. These findings contribute to further insight into the process of thrombus regression, Furthermore high DD levels might help to identify the patients with a poor prognosis and could be useful to judge the efficacy of anticoagulant treatment.
introduction
Deep venous thrombosis (DVT) is a common disease with consider able morbidity. Patients with acute DVT are usually treated with an initial course of heparin (5 to 10 days) followed by at least 3 months of oral anticoagulant therapy (1,2). The extent of thrombus regression at the time of withdrawing anticoagulant therapy is usually not known.
The past few years duplex scanning (DS) has become a reliable technique to diagnose DVT. Because of its non-invasive nature, the technique is also useful for follow-up of DVT. A few studies have prospectively assessed the outcome of acute DVT by means of DS. It 
Labomtoiy Testing
At the time of diagnosis and at the end of initial therapy from all patients 4.5 ml of blood was drawn into a vacutainer tube containing 0. 
the mean age of the patients was higher in the group that did not normalize. All patients with distal DVT normalized within 3 months.
For the whole group of patients DD decreased significantly during heparin treatment (p = 0.0001). There was no significant relation between the location of initial thrombus and DD levels.
The ROC curve for DD levels at the end of heparin therapy is shown in Fig. 1 . A cut-off value of 1200 ng/ml was chosen based on optimal sensitivity and minimal false positive fraction. Figure 2 shows the comparison of DD levels before and after heparin treatment between the group of patients that normalized after three months and the group that did not normalize. DD levels at the end of initial therapy were significantly higher in the group of patients that did not normalize (p = 0.003). However, there was a large overlap of individual values between the groups. Mean values of the markers at the end of initial therapy remained elevated. While the patients with distal DVT (n = 5) were excluded DD levels at the end of heparin treatment were still significant (p = 0,006). Figure 3 shows the DD levels of the same group of patients when the patients with an established malignancy (n = 8) are excluded. It shows that the differences in DD levels between the group that normalized and the group that did not normalize were even more significant (p = 0.0004). Table 2 shows the odds ratios of different DD levels to be associated with poor resolution of DVT for the whole group of patients and for the patients without malignancy. A ninefold excess tendency was seen for DD levels > 1200 ng/ml after initial therapy to be associated with poor resolution of the DVT (odds ratio 9.0,0.95 Cl 2.3-35.4). The odds ratio for levels >1200 ng/ml after initial therapy for the group of patients without malignancy was 17.5,0.95 Cl 3.3-92.5,
Discussion
The objective of this study was to assess the time course of DD, a specific fibrinolytic parameter, in patients presenting an acute DVT treated with standard anticoagulant treatment. The second objective was to investigate the predictive value of this parameter for regression of DVT, because incomplete regression might lead to long-term complications like recurrent DVT or the post-thrombotic syndrome.
The recent development of assays for activation markers of the haemostatic and fibrinolytic system allows rapid and specific determi nation of these parameters in plasma. We used DD as a specific fibrin degradation product being increasingly used as a screening test for diagnosis of DVT because DD is elevated in the presence of active thrombosis. A high sensitivity and negative predictive value of DD assays has been reported in large series of patients (6) (7) (8) .
In agreement with Mirshahi et al, (11) and Arcelus et al. (14) we found a trend but no significant correlation of DD levels with the location of the DVT. An explanation for this might be the influence of the age of the trombus and the fact that the relation between fibrin mass and fibrin-split products also depends on the activity of the fibrinolytic system, which varies among patients. Also extra vascular fibrin deposition may contribute to elevated DD. Because of these confounders DD levels are probably of no value for the prediction of thrombus size in individual patients.
Previous reports indicate that, at initiation of heparin therapy, a sharp decrease in DD levels occurs within 1-3 days, followed by a continuous and slow decline towards the normal range (9-11). There are anecdotal reports on patients with thromboembolic recurrence and secondary increase of DD levels (9). In the current study DD also decreased significantly during the initial phase of treatment. Remarka bly in only 4 patients DD was completely normalized (<500 ng/ml) at the end of initial heparin therapy. An explanation could be that fibrinolysis is a long lasting phenomenon which occurs independently of thrombin generation and of heparin therapy. Another possibility could be linked to the relatively long DD half-life (8 h). We decided to evaluate outcome of DVT after 3 months because that is currently the recommended time to withdraw anticoagulant treatment after a first period of DVT (15) . There are two other studies comparing levels of plasma markers to clinical outcome, The first study compares DD levels with venography after 10 days (10), During this period a relation was found between decrease of DD and regression of DVT. Arcelus et al. evaluated plasminogen activator inhibitor (PAI) and DD levels with trombus regression during 6 months (14), They found a significant relation between PAI levels and a trend between DD levels and outcome of DVT, Our results demonstrate a significant relation between DD levels after initial therapy and regression of DVT, even though patients with distal DVT were excluded. Also a ninefold excess tendency was seen for DD levels >1200 ng/ml to be associated with poor resolution of the DVT (odds ratio 9.0,0.95 Cl 2.3-35.4). Figure 3 shows that the differences between the group that normal ized and the group that did not normalize were even more significant when patients with an established malignancy (n = 8) were excluded. For this group of patients the odds ratio for DD levels >1200 ng/ml associated with poor resolution was 17,5 (0,95 Cl 3.3-92.5), This is not surprising concerning the fact that different types of malignancy also cause elevated DD levels (16) (17) (18) ; it was demonstrated that the accuracy of DD in diagnosis of DVT is also less in patients with a malignancy (19) .
In conclusion, this study provides evidence that increased DD levels during the initial heparin treatment, might be related to outcome of DVT after 3 months, especially in patients without malignancy. To estimate the predictive value of an elevated DD validation in a separate group of patients is needed, These findings may contribute to further insight into the process of thrombus regression. Also it could help to identify the patients with a poor prognosis and may be useful to judge the efficacy of anticoagulant treatment. Whether or not serial measure ment of DD is useful for monitoring and predicting regression of DVT, at what time interval this should be performed and what should be the best cut-off value are questions for future studies in larger patient populations.
